Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Cahyadi, Oscar [VerfasserIn]   i
 Bauder, Markus [VerfasserIn]   i
 Meier, Benjamin [VerfasserIn]   i
 Caca, Karel [VerfasserIn]   i
 Schmidt, Arthur [VerfasserIn]   i
Titel:Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding
Titelzusatz:a single center experience
Verf.angabe:Authors Oscar Cahyadi, Markus Bauder, Benjamin Meier, Karel Caca, Arthur Schmidt
E-Jahr:2017
Jahr:08. November 2017
Umfang:6 S.
Illustrationen:Illustrationen
Fussnoten:Gesehen am 11.11.2024
Titel Quelle:Enthalten in: Endoscopy International Open
Ort Quelle:Stuttgart : Thieme, 2013
Jahr Quelle:2017
Band/Heft Quelle:5(2017), 11 vom: Nov., Seite E1159-E1164
ISSN Quelle:2196-9736
Abstract:Background and study aims: TC-325 (Hemospray, Cook Medical) is a powder agent for endoscopic hemostasis in patients with upper gastrointestinal bleeding (UGIB). Although most publications are based on case-reports and retrospective studies, data on efficacy are promising. Here we report our experience with TC-325 for diffuse or refractory UGIB. Patients and methods: Data on patients receiving TC-325 for endoscopic hemostasis from November 2013 to February 2017 at our center were analyzed retrospectively. Primary endpoints were technical success (successful immediate hemostasis) and clinical success (effective hemostasis and no recurrent bleeding). Secondary endpoints were recurrent bleeding within 3 and 7 days, hospital mortality and TC-325 associated complications. TC-325 was used for bleeding not amenable to standard endoscopic treatment (e. g. diffuse bleeding) or as salvage therapy after failure of conventional methods. Results: Fifty-two patients received TC-325 treatment. Most of the patients were treated for peptic ulcer bleeding (18/52 patients, 34.6 %) and post-interventional bleeding (13/52 patients, 25 %). Hemospray was used in 23/52 (44.2 %) patients as monotherapy and in 29/52 (55.8 %) patients as a salvage therapy. Application of the powder on the bleeding source was successful in all patients with no therapy-related adverse events (AEs). Immediate hemostasis was achieved in 51/52 (98.1 %) patients. Recurrent bleeding within 3 and 7 days was observed in 22/51 and 25/51 patients respectively (43.1 % and 49 %). The overall clinical success was 56.9 % on day 3 and 51 % on day 7. Total mortality was 15.4 % (8 patients), bleeding associated mortality was 3.8 % (2 patients). There were no therapy-related AEs. Conclusions: TC-325 showed a high technical success rate as monotherapy for bleeding sources not amenable to standard methods or as an “add-on” therapy after unsuccessful hemostasis. However, rebleeding was frequent in this cohort and further studies are warranted to exactly define a treatment algorithm for TC-325 use.
DOI:doi:10.1055/s-0043-118794
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1055/s-0043-118794
 kostenfrei: Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-118794
 DOI: https://doi.org/10.1055/s-0043-118794
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1908215275
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69272366   QR-Code
zum Seitenanfang